Trulieve Cannabis Corp. — Q3 2022 Form 10-Q
Business context and period. The unaudited report covers the three and nine months ended September 30, 2022. Trulieve is a vertically integrated, U.S. cannabis operator; it reported 176 dispensaries at quarter-end and said most revenue came from Florida, followed by Arizona and Pennsylvania. In July 2022, it discontinued Nevada operations and presented them as discontinued operations.
Financial performance and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $300.8 million | $224.1 million | $937.6 million | $633.0 million |
| Gross profit / margin | $168.0 million / 56% | $153.9 million / 69% | $532.3 million / 57% | $433.7 million / 69% |
| Operating income (loss) | $(27.8) million | $66.3 million | $44.7 million | $215.1 million |
| Net income (loss) attributable to common shareholders | $(114.6) million | $18.6 million | $(169.0) million | $89.6 million |
| Adjusted EBITDA | $98.8 million | $98.0 million | $315.5 million | $283.7 million |
At September 30, cash and cash equivalents were $114.5 million, down from $230.1 million at December 31, 2021. For the first nine months, operating cash flow was $(31.9) million, investing cash flow $(179.0) million, and financing cash flow $91.9 million. Inventory was $301.2 million, versus $209.9 million at year-end; the inventory obsolescence allowance rose to $5.8 million from $1.5 million.
Private placement notes were $540.3 million net ($555.0 million principal); other notes payable totaled $12.8 million. The balance sheet also included operating, finance, and construction finance liabilities. Management said existing cash was expected to cover anticipated cash needs for at least 12 months, while noting future funding needs could require additional debt or equity.
Material changes and unusual items
- Revenue rose 34% in Q3 and 48% year to date, driven by organic retail growth, acquisitions including Harvest, additional stores, and market expansion.
- Gross margin fell to 56% from 69% in Q3. Management cited higher depreciation, increased wholesale sales, newer facilities operating below scale, and sales of third-party products in less vertically integrated markets.
- Q3 operating results included $52.0 million of impairment and disposal expense. This included a $46.2 million property and equipment disposal loss, primarily related to repositioning assets in the Southeast. Year-to-date impairment and disposal expense was $70.2 million.
- Nevada discontinued operations generated a $38.1 million Q3 net loss, including a $49.1 million impairment and disposal charge; the nine-month loss was $42.3 million.
- Q3 general and administrative expense included a $10.0 million contribution to the Smart and Safe Florida campaign. The company also accrued $12.6 million year to date for probable Watkins acquisition earnouts.
- Income tax expense was $28.2 million in Q3 despite a pretax loss; the filing cites cannabis tax restrictions under IRC Section 280E and a more favorable position on intercompany management fees adopted in the quarter.
Outlook, risks, and controls
No quantified revenue, earnings, or cash-flow guidance is provided. Management expects operating and sales-and-marketing costs to remain affected by expansion, staffing, compliance, and additional locations. It cited lower margins in wholesale and less vertically integrated markets and anticipated ongoing investment in infrastructure.
Key risks include cannabis’s continued federal illegality, state licensing and regulatory compliance, restricted access to banking and bankruptcy protections, Section 280E taxation, competition, execution of acquisitions and growth, and significant debt and contractual obligations. The company reported no pending or threatened lawsuits expected to have a material effect, but recorded $11.4 million for pending litigation and $1.6 million for sales-tax matters.
Management concluded disclosure controls were ineffective at September 30, 2022 because an IT access and program-change-management material weakness remained. Remediation was underway and not yet complete. A separate previously reported weakness concerning financial-reporting personnel was stated to have been remediated.
Investor verification points
- Assess whether revenue growth can translate into improved margins and positive operating cash flow, given the margin decline and inventory build.
- Review the nature and recurrence of asset impairments, Nevada exit costs, and other adjustments excluded from Adjusted EBITDA.
- Verify liquidity and debt-service capacity, including the status of the $6.1 million note refinancing due in December 2022 and obligations under the 2024 and 2026 notes.
- Track inventory aging and the adequacy of the obsolescence allowance, as well as Watkins earnout accruals and other contingencies.
- Monitor remediation and testing of the remaining IT-related material weakness and the effects of Section 280E and federal cannabis law.